Jazz Pharmaceuticals PLC Form 4 insider transactions

Director Seamus Mulligan reports acquisition of restricted stock units in Jazz Pharmaceuticals.

Director Patrick Kennedy reports acquisition of restricted stock units and disposal of ordinary shares in Jazz Pharmaceuticals.

Director Laura Hamill reports acquisition and disposal of Jazz Pharmaceuticals ordinary shares and restricted stock units.

Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals, reported the sale of 163 ordinary shares on June 7, 2024.

Neena M Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals plc, sold 5,000 ordinary shares at an average price of $109.65 on May 3, 2024.

Renee D. Gala, President & COO of Jazz Pharmaceuticals, disposed of 1,736 ordinary shares on April 5, 2024, to cover tax obligations arising from vesting restricted stock units.

Patricia Carr, SVP, Chief Accounting Officer of Jazz Pharmaceuticals plc, sold shares of the company's ordinary stock on March 6th and 7th, 2024, to satisfy tax obligations arising from vesting restricted stock units.

Renee D. Gala, President & COO of Jazz Pharmaceuticals, reports the disposal of 3,622 ordinary shares to cover tax obligations arising from vesting restricted stock units on March 5, 2024.

Samantha Pearce, SVP, Head of Europe & International at Jazz Pharmaceuticals, reports the disposal of 2,474 ordinary shares to cover tax obligations.

Neena M Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals, reports the disposal of 3,432 ordinary shares to cover tax obligations.

Robert Iannone, EVP, Global Head of R&D at Jazz Pharmaceuticals, disposed of shares to cover tax obligations arising from vesting restricted stock units.

Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, disposed of 22,436 ordinary shares on March 5, 2024, to satisfy tax obligations related to vesting restricted stock units.

Mary Elizabeth Henderson, SVP, Technical Operations at Jazz Pharmaceuticals, reports the acquisition of 5,178 ordinary shares and disposal of 15,941 ordinary shares on March 1, 2024.

Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals, received 2,987 restricted stock units on March 1, 2024, under the company's 2011 Equity Incentive Plan.

Samantha Pearce, SVP, Head of Europe & International at Jazz Pharmaceuticals, reports acquisition and disposal of ordinary shares.

Neena M Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals, reports the acquisition of 12,348 ordinary shares and subsequent holdings of 45,061 shares.

EVP, Global Head of R&D at Jazz Pharmaceuticals, Robert Iannone, reports acquisition of 16,928 ordinary shares and disposal of shares on March 1, 2024.

Renee D Gala, President & COO of Jazz Pharmaceuticals, reports the acquisition of 19,916 ordinary shares and a grant of restricted stock units.

Bruce Cozadd, Chairman & CEO of Jazz Pharmaceuticals, reports the acquisition of restricted stock units under the company's 2011 Equity Incentive Plan.

Director Patrick Kennedy reports acquiring 1,423 shares of Jazz Pharmaceuticals common stock on March 1, 2024, through restricted stock units.

Philip L. Johnson, EVP & Chief Financial Officer of Jazz Pharmaceuticals, reports the acquisition of ordinary shares, including restricted stock units, in a recent SEC Form 4 filing.